A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029
This study is recruiting at 12 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumor
- Advanced Breast Cancer
- Advanced Ovarian Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama at Birmingham · Birmingham, AL
California · 4
- Providence St. Jude Medical Center · Fullerton, CA
- Marin Cancer Care · Greenbrae, CA
- Moores Cancer Center · La Jolla, CA
- Hoag Memorial Hospital Presbyterian · Newport Beach, CA
Missouri · 1
- Washington University School of Medicine · St Louis, MO
New Hampshire · 1
- Dartmouth-Hitchcock Medical Center · Lebanon, NH
New York · 3
- Roswell Park Cancer Institute · Buffalo, NY
- Northwell Health-Cancer Institute · New Hyde Park, NY
- Memorial Sloan Kettering Cancer Center · New York, NY
Texas · 2
- START Dallas Fort Worth · Fort Worth, TX
- NEXT Oncology · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.